Precision Medicine in Prostate Cancer VL

PROfound Study - PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations - Maha Hussain

Details
Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it's intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cance...

PSMA Targeted Therapies Presentation - Michael Hofman

Details
Professor Michael Hofman presented on prostate-specific membrane antigen (PSMA) targeted therapies during the Management of castration-resistant prostate cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, presenting data from both of his groups in Australia. Dr. Hofman highlights the progress of a single-centre, single-arm, phase 2 study; [177Lu]-PSMA-617 radi...

Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman

Details
Charles Ryan and Michael Hofman share in a discussion on the use of new imaging techniques in prostate cancer, the sensitivity of imaging and the use of theranostics PSMA targeted therapies for metastatic castrate-resistant prostate cancer. Michael Hofman details the quick advance of PSMA imaging in Australia. He highlights PSMA tracers including Gallium-68 and PSMA-Based [18F]DCFPyL PET/CT and th...

Role of PARP Inhibitors in Prostate Cancer - Evan Yu

Details
Neal Shore and Evan Yu share in a discussion on the evolving role of PARP inhibitors in the treatment of mCRPC. Dr. Yu reviews the early interim results of rucaparib in the TRITON-2 study and points out the intricacies that must be considered when evaluating all the recent data involving DNA mutations. Drs. Shore and Yu discuss the class of PARP inhibitors in clinical development and what makes ea...

Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais

Details
Jeremie Calais discusses his PCF funded research on 177 Lu-PSMA-617 with respect to resistance patterns that develop to treatment along with primary resistance. Drs. Calais and Ryan discuss patient and tumor characteristics for both those demonstrating effectiveness to therapy and those that develop resistance or have primary resistance. Biographies: Jeremie Calais, MD, MSc Assistant Professor at...

Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer by Michael Hofman

Details
Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically. Biographies: Michael Hofman, MBBS (Hon...

Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce

Details
(Length of Discussion: 8 min) Charles Ryan and Alan Bryce discuss TRITON2 results that provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with homologous recombination deficiency. Alan presents the molecular selection criteria, the design of the trial and the initial look at the first 85 patients in this study of he...

State of the Art: Treatment Update in Prostate Cancer- Oliver Sartor

Details
Oliver Sartor and Charles Ryan discuss radioligand therapy, differentiating radioisotopes by properties and clinical application. They move to review the PSMA targeted agents and the clinical use of these agents in the treatment of prostate cancer. Biographies: A. Oliver Sartor, MD, Professor of Medicine, Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Resea...

PSMA Imaging and Theranostics: Future Impact to Patient Management– Robert Flavell

Details
(Length of presentation: 30 min) In an interview with Phil Koo, Robert Flavell describes diagnostic and therapeutic applications of new agents in the management of patients with prostate cancer with initial high-risk diagnosis and biochemical recurrence. Biographies: Robert R. Flavell, MD, Ph.D., Assistant Professor in Residence Department of Radiology, Section of Nuclear Medicine, University of C...
email news signup